source
- Axiom plans Hong Kong IPO, hoping to carve new path for US biotechsAxiom Biosciences is thinking outside of the box, betting on a public debut in Hong Kong to raise capital and grow into a global company.BioSpace · 9d ago↗ source
- Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsEli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…BioSpace · 10d ago↗ source
- FDA’s radical transparency policy for rejections runs into legal uncertaintyHaving started to publish CRLs without consulting the public, the FDA is under pressure to change course amid concerns it failed to openly and fully evaluate a complex issue.